<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2682</journal-id><journal-id journal-id-type="pmc-domain">cas</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11159823</article-id><article-id pub-id-type="pmcid-ver">PMC11159823.1</article-id><article-id pub-id-type="pmcaid">11159823</article-id><article-id pub-id-type="pmcaiid">11159823</article-id><article-id pub-id-type="pmid">17640301</article-id><article-id pub-id-type="doi">10.1111/j.1349-7006.2007.00554.x</article-id><article-id pub-id-type="publisher-id">CAS554</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Experimental Therapeutics and Clinical Medicine</subject></subj-group></subj-group></article-categories><title-group><article-title>Sipholenol A, a marine&#8208;derived sipholane triterpene, potently reverses P&#8208;glycoprotein (ABCB1)&#8208;mediated multidrug resistance in cancer cells</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="Z">Zhi</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="a2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cr2" contrib-type="author"><name name-style="western"><surname>Jain</surname><given-names initials="S">Sandeep</given-names></name><xref rid="a3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cr3" contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="IW">In&#8208;Wha</given-names></name><xref rid="a4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cr4" contrib-type="author"><name name-style="western"><surname>Peng</surname><given-names initials="XX">Xing&#8208;Xiang</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cr5" contrib-type="author"><name name-style="western"><surname>Abraham</surname><given-names initials="I">Ioana</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cr6" contrib-type="author"><name name-style="western"><surname>Youssef</surname><given-names initials="DTA">Diaa T.A.</given-names></name><xref rid="a5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cr7" contrib-type="author" corresp="yes"><name name-style="western"><surname>Fu</surname><given-names initials="LW">Li&#8208;Wu</given-names></name><xref rid="a2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cr8" contrib-type="author"><name name-style="western"><surname>El Sayed</surname><given-names initials="K">Khalid</given-names></name><xref rid="a3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cr9" contrib-type="author"><name name-style="western"><surname>Ambudkar</surname><given-names initials="SV">Suresh V.</given-names></name><xref rid="a4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cr10" contrib-type="author" corresp="yes"><name name-style="western"><surname>Chen</surname><given-names initials="ZS">Zhe&#8208;Sheng</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="a1">
<label>
<sup>1</sup>
</label>Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St John's University, Jamaica, NY 11439, USA;</aff><aff id="a2">
<label>
<sup>2</sup>
</label>State Key Laboratory for Oncology in South China, Cancer Center, Sun Yat&#8208;Sen University, Guangzhou 510060, China;</aff><aff id="a3">
<label>
<sup>3</sup>
</label>Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209, USA;</aff><aff id="a4">
<label>
<sup>4</sup>
</label>Laboratory of Cell Biology, NCI, NIH, Bethesda, MD 20892&#8208;4256, USA;</aff><aff id="a5">
<label>
<sup>5</sup>
</label>Department of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
To whom correspondence should be addressed. E&#8208;mail: <email>chenz@stjohns.edu</email> or <email>fulw@mail.sysu.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>7</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2007</year></pub-date><volume>98</volume><issue seq="14">9</issue><issue-id pub-id-type="pmc-issue-id">464484</issue-id><issue-id pub-id-type="doi">10.1111/cas.2007.98.issue-9</issue-id><fpage>1373</fpage><lpage>1380</lpage><history><date date-type="received"><day>13</day><month>3</month><year>2007</year></date><date date-type="rev-recd"><day>11</day><month>5</month><year>2007</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2007</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>07</month><year>2007</year></date></event><event event-type="pmc-live"><date><day>08</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-08 11:25:13.843"><day>08</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAS-98-1373.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAS-98-1373.pdf"/><abstract><p>Through extensive screening of marine sponge compounds, the authors have found that sipholenol A, a sipholane triterpene isolated from the Red Sea sponge, <italic toggle="yes">Callyspongia siphonella</italic>, potently reversed multidrug resistance (MDR) in cancer cells that overexpressed P&#8208;glycoprotein (P&#8208;gp). In experiments, sipholenol A potentiated the cytotoxicity of several P&#8208;gp substrate anticancer drugs, including colchicine, vinblastine, and paclitaxel, but not the non&#8208;P&#8208;gp substrate cisplatin, and significantly reversed the MDR of cancer cells KB&#8208;C2 and KB&#8208;V1 in a concentration&#8208;dependent manner. Furthermore, sipholenol A had no effect on the response to cytotoxic agents in cells lacking P&#8208;gp expression or expressing MDR protein 1 or breast cancer resistance protein. Sipholenol A (IC<sub>50</sub>&#160;&gt;&#160;50&#160;&#181;M) is not toxic to all the cell lines that were used, regardless of their membrane transporter status. Accumulation and efflux studies with the P&#8208;gp substrate [<sup>3</sup>H]&#8208;paclitaxel demonstrated that sipholenol A time&#8208;dependently increased the intracellular accumulation of [<sup>3</sup>H]&#8208;paclitaxel by directly inhibiting P&#8208;gp&#8208;mediated drug efflux. In addition, sipholenol A did not alter the expression of P&#8208;gp after treating KB&#8208;C2 and KB&#8208;V1 cells for 36&#160;h and 72&#160;h. However, it efficaciously stimulated the activity of ATPase of P&#8208;gp and inhibited the photolabeling of this transporter with its transport substrate [<sup>125</sup>I]&#8208;iodoarylazidoprazosin. Overall, the present results indicate that sipholenol A efficiently inhibits the function of P&#8208;gp through direct interactions, and sipholane triterpenes are a new class of potential reversing agents for treatment of MDR in P&#8208;gp&#8208;overexpressing tumors. (<italic toggle="yes">Cancer Sci</italic> 2007; 98: 1373&#8211;1380)</p></abstract><counts><fig-count count="6"/><table-count count="2"/><equation-count count="0"/><ref-count count="37"/><page-count count="8"/><word-count count="5798"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2007</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.4 mode:remove_FC converted:05.06.2024</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>